-- Presentations to be webcast on www.exelixis.com
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 21, 2017--
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s President and Chief Executive Officer, will provide
an overview of the company at the following two investor conferences in
the coming weeks:
Piper Jaffray 29th Annual Healthcare Conference: Exelixis’
presentation is scheduled for 11:00 AM EST / 8:00 AM PST on Tuesday,
November 28, 2017 in New York, NY.
Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference: Exelixis’
presentation is scheduled for 12:05 PM EST / 9:05 AM PST on Wednesday,
November 29, 2017 in Boston, MA.
To access the webcast link, log onto www.exelixis.com
and proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s website at
least 15 minutes prior to the presentation to ensure adequate time for
any software download that may be required to listen to the webcast. A
replay will also be available at the same location for 14 days.
Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. We discovered our lead
compounds, cabozantinib and cobimetinib, and advanced them into clinical
development before entering into partnerships with leading
biopharmaceutical companies in our efforts to bring them to patients
globally. We are steadfast in our commitment to prudently reinvest in
our business to maximize the potential of our pipeline. We intend to
supplement our existing therapeutic assets with targeted business
development activities and internal drug discovery – all to deliver the
next generation of Exelixis medicines and help patients recover stronger
and live longer. Exelixis recently earned a spot on Deloitte’s
Technology Fast 500 list, a yearly award program honoring the 500
fastest-growing companies over the past four years. For more information
about Exelixis, please visit www.exelixis.com
or follow @ExelixisInc on Twitter.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171121006080/en/
Source: Exelixis, Inc.
EVP, Public Affairs and Investor
For Exelixis, Inc.